Incretin mimetic therapy for type 2 diabetes has been on the market for more than 10 years. Find out what you've learned about the GLP-1 agonists, here.
While we wait for results from FDA-mandated CV outcomes studies by SGLT2I makers, there is plenty of (positive) speculation.
The ADA provides an abridged version for PCPs of its annual Standards of Medical Care. Our slides summarize 6 updates important to primary care.
It's probably too early to pass judgment but data from clinical trials point to decreased bone mineral density and increased treatment-emergent fractures in patients taking the new antidiabetes drugs.
New research shows certain women are 43 times more likely to develop type 2 diabetes mellitus after childbirth.
Evidence-based recommendations on the intake of free sugars to reduce the risk of noncommunicable diseases are the ingredients of a new WHO guideline. Find the recipe in these slides.
Medical and lifestyle interventions successfully lowered the risk of type 2 diabetes in women with a history of gestational diabetes.
Since June of 2014, the US FDA has approved a number of drugs for a variety of endocrine-related diseases. Here are 10 of them.
Cardiovascular disease is the underlying cause of death in more than 60% of patients with T2DM. GLP-1 receptor agonists have shown promising cardioprotective effects.
Women with polycystic ovary syndrome (PCOS) are at increased risk for metabolic and heart diseases and nearly twice as likely to be hospitalized.